IDEMIA
30.6.2020 08:02:13 CEST | Business Wire | Press release
The supervisory board of IDEMIA has appointed Pierre Barrial as the new President & CEO of the Group, replacing Yann Delabrière who resumes his previous role as Chairman of the Board. Matthew Cole, who has joined the Group, has taken on Pierre Barrial’s previous position as head of the Secure Enterprise Transactions (SET) division.
Over the last 18 months, IDEMIA has restored its growth and cash generation performance after the creation and successful integration of IDEMIA. Yann, who became President & CEO on October 18th 2018, will now be returning to his role as Chairman of the Board with effect from July 1st , 2020, where he will continue to contribute his strategic and governance insights to the company.
Pierre Barrial will succeed Yann as the Group’s President & CEO. He brings over 25 years’ experience with multinational and multicultural tech companies serving both the government and enterprise sectors. Pierre was in charge of SET, having previously managed IDEMIA’s Mobile Operators then Financial Institutions activities, both today part of the SET division. He has partnered with Yann since the beginning of the year as Deputy CEO. Pierre will become IDEMIA’s Group President & CEO starting July 1st , 2020.
Matthew Cole is appointed as head of the SET division, replacing Pierre Barrial. Matthew brings a wealth of experience in this space, having been President of Cubic Transportation Systems, the leading integrator of payment and information solutions and related services for intelligent travel applications in the transportation industry. He will be based in the US and will sit on the Group Executive Committee, as SET division’s CEO.
Yann Delabrière stated: “After a carefully prepared succession plan, we have chosen a world-class executive, Pierre Barrial, to manage the Group. IDEMIA has demonstrated remarkable resilience since the beginning of this year and our business fundamentals are strong and bode well for the future. On behalf of the Board, I wish Pierre all the very best in his new role.”
Pierre Barrial added: “I’m honored and excited to have been chosen as CEO of the Group. IDEMIA has an extremely committed team of 15,000 employees worldwide and together, we’ll continue to serve our clients regardless of the circumstances. I am also proud to head a company whose purpose, since its creation, is to make the world a safer place, whenever and wherever Identity & Security matter in an increasingly digital world. With recent events, this is more true than ever.”
Matthew Cole said: “I am thrilled and proud to join IDEMIA as CEO of the SET division. I plan to work hand in hand with my teams and Group senior management to bring the company’s strategy and growth targets to fruition.”
About Yann Delabrière
Yann Delabrière is a graduate of Ecole Normale Supérieure and Ecole Nationale d’Administration and has a postgraduate degree in mathematics. He began his career at the Committee of Public Accounts (Cour des Comptes) before working for the French External Trade Minister. He then became Chief Financial Officer for the French export credit agency, COFACE, followed by Printemps Group, before becoming Chief Financial Officer for PSA Peugeot Citroën in 1990 and, from 1998, was Chairman and Chief Executive Officer of Banque PSA Finance and sat on the PSA Peugeot Citroën Executive Committee. In 2007 Yann was appointed Chairman and Chief Executive Officer of Faurecia. From June 2017 to February 2018, he chaired the Zodiac Aerospace executive board. From 2004 to May 2018 he was a director of Cap Gemini, from 2012 to 2016 a director of Société Générale and since March 2017 has been a director of Alstom. He has chaired the IDEMIA executive board since October 2018 having previously chaired the IDEMIA supervisory board for a 10-month period.
About Pierre Barrial
Pierre Barrial graduated from Paris School of Business. He comes with over 25 years experience with multinational and multicultural firms and agencies from a broad array of industries including ICT and security, serving both the public and private sectors. After Pierre joined IDEMIA in 2013, he managed the Group’s Latin American operations followed by the Mobile Operators business, the Financial Institutions business and SET. Previously, Pierre worked in various jobs for Bull Group in South Africa, Italy, Poland and Brazil.
About Matthew Cole
Matthew Cole holds an MBA from Oxford Brookes University and is also Chartered Certified Accountant. In 2003 he joined Cubic Corporation, the world leader in smart and contactless payments for transportation. During his time at Cubic Matthew held several senior finance positions before successfully heading up the company’s Asia-Pacific operations followed by global Strategy and Business Development. In 2015, he became President of Cubic Transportation Systems. Before Cubic Corporation, Matthew held several positions with blue-chip multinational firms including Endemol, British Airways, Mitsui, First Choice and Schlumberger.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005779/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
